REFERENCE
Tucker D, Valentine WJ, Nielsen S, Townsend C, Kotchie R, Scheijbeler H.Evaluating the cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for the treatment of type 2 diabetes in a Spanish setting. Value in Health 10: A263 (plus poster) abstr. PDB30, No. 6, Nov-Dec 2007
Rights and permissions
About this article
Cite this article
Insulin aspart/insulin protamine aspart cost-effective for T2DM. Pharmacoecon. Outcomes News 540, 8 (2007). https://doi.org/10.2165/00151234-200705400-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705400-00013